Please use this identifier to cite or link to this item: https://doi.org/10.1038/srep34310
DC FieldValue
dc.titleCD16 is indispensable for antibodydependent cellular cytotoxicity by human monocytes
dc.contributor.authorYeap, W.H
dc.contributor.authorWong, K.L
dc.contributor.authorNORIKO SHIMASAKI
dc.contributor.authorTeo, E.C.Y
dc.contributor.authorQuek, J.K.S
dc.contributor.authorYong, H.X
dc.contributor.authorDiong, C.P
dc.contributor.authorBertoletti, A
dc.contributor.authorLinn, Y.C
dc.contributor.authorWong, S.C
dc.date.accessioned2020-10-22T02:49:02Z
dc.date.available2020-10-22T02:49:02Z
dc.date.issued2016
dc.identifier.citationYeap, W.H, Wong, K.L, NORIKO SHIMASAKI, Teo, E.C.Y, Quek, J.K.S, Yong, H.X, Diong, C.P, Bertoletti, A, Linn, Y.C, Wong, S.C (2016). CD16 is indispensable for antibodydependent cellular cytotoxicity by human monocytes. Scientific Reports 6 : 34310. ScholarBank@NUS Repository. https://doi.org/10.1038/srep34310
dc.identifier.issn20452322
dc.identifier.urihttps://scholarbank.nus.edu.sg/handle/10635/178861
dc.description.abstractAntibody dependent cellular cytotoxicity (ADCC) is exerted by immune cells expressing surface Fc? receptors (Fc?Rs) against cells coated with antibody, such as virus infected or transformed cells. CD16, the Fc?RIIIA, is essential for ADCC by NK cells, and is also expressed by a subset of human blood monocytes. We found that human CD16- expressing monocytes have a broad spectrum of ADCC capacities and can kill cancer cell lines, primary leukemic cells and hepatitis B virus infected cells in the presence of specific antibodies. Engagement of CD16 on monocytes by antibody bound to target cells activated ?2 integrins and induced TNF? secretion. In turn, this induced TNFR expression on the target cells, making them susceptible to TNF? mediated cell death. Treatment with TLR agonists, DAMPs or cytokines, such as IFN?, further enhanced ADCC. Monocytes lacking CD16 did not exert ADCC but acquired this property after CD16 expression was induced by either cytokine stimulation or transient transfection. Notably, CD16+ monocytes from patients with leukemia also exerted potent ADCC. Hence, CD16+ monocytes are important effectors of ADCC, suggesting further developments of this property in the context of cellular therapies for cancer and infectious diseases. © The Author(s) 2016.
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceUnpaywall 20201031
dc.typeArticle
dc.contributor.departmentPAEDIATRICS
dc.contributor.departmentDUKE-NUS MEDICAL SCHOOL
dc.description.doi10.1038/srep34310
dc.description.sourcetitleScientific Reports
dc.description.volume6
dc.description.page34310
dc.published.stateUnpublished
Appears in Collections:Elements
Staff Publications

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1038_srep34310.pdf3.92 MBAdobe PDF

OPEN

NoneView/Download

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons